AMARIN CORPORATION PLC

Consensus Amarin Corporation plc

Stocks

AMRN

US0231114044

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 06/11/2026 GMT			5-day change	1st Jan Change
11.61 ^USD	+0.30%		-4.13%	-16.80%

11-06	European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading	MT
11-03	European Equities Traded in the US as American Depositary Receipts Decline Slightly in Tuesday Trading	MT

Evolution of the Average Target: Amarin Corporation plc

Evolution of the Average Target - Amarin Corporation plc

Evolution of the Target Price: Amarin Corporation plc

Evolution of the Target Price - Amarin Corporation plc

Changes in Analyst Recommendations: Amarin Corporation plc

a27a1d85c8e55a53ca7462a42c2a4.vC661o7dRxvZGoTqpcQpEwuP3spw3vtqk4OSxrCTZlo.8BfvveivK1aVbfSf94ZQcmq785VDtZUz6dzRrPbdMiDuHY6d-J8vYoBu0Q~8c0357c2f7b7791dcc6790e483a09640

Analysts' recommendations: Amarin Corporation plc

27/10/25	Amarin issues statement supporting FDA's action to revise labeling for fenofibrate drugs reinforcing a lack of cardiovascular benefit	RE
25/06/25	RBC Ups Recordati's Price Target on Cardiovascular Drug European Licensing Deal	MT
25/10/23	Jefferies Downgrades Amarin to Hold From Buy, Cuts Price Target to $1 From $3	MT
19/07/23	Northland Adjusts Price Target on Amarin to $1.25 From $2, Maintains Market Perform Rating	MT
06/01/23	Jefferies Upgrades Amarin to Buy From Hold, Adjusts Price Target to $3 From $1.30	MT
19/10/22	SVB Securities Adjusts Amarin's Price Target to $2 From $3, Maintains Market Perform Rating	MT
06/05/22	JPMorgan Downgrades Amarin to Underweight From Neutral	MT
05/05/22	HC Wainwright Lowers Amarin to Neutral From Buy, Price Target to $3 From $10	MT
05/05/22	SVB Leerink Downgrades Amarin to Market Perform From Outperform, Adjusts Price Target to $3 From $10	MT
05/05/22	Northland Downgrades Amarin to Market Perform From Outperform, Adjusts Price Target to $2 From $9	MT
16/02/22	SVB Leerink Adjusts Amarin's Price Target to $10 from $11, Maintains Outperform Rating	MT
31/01/22	SVB Leerink Adjusts Amarin's Price Target to $11 from $12, Keeps Outperform Rating	MT
12/05/21	Amarin : Goldman Sachs Downgrades Amarin to Sell From Neutral, Adjusts Price Target to $5 From $6	MT
01/02/21	Amarin : SVB Leerink Adjusts Price Target on Amarin to $16 From $12, Maintains Outperform Rating	MT
23/12/20	Amarin : Goldman Sachs Adjusts Amarin's Price Target to $6 From $8, Maintains Neutral Rating	MT
07/12/20	Amarin : Citigroup Adjusts Amarin's Price Target to $7 from $12, Maintains Buy Rating	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	AMARIN CORPORATION PLC			-	-	+11.97%
	WUXI APPTEC CO., LTD.					+37.65%
	LONZA GROUP AG					+7.56%
	ARGENX SE					+23.18%
	BEONE MEDICINES AG					+7.52%
	IQVIA HOLDINGS INC.					+14.74%
	REVOLUTION MEDICINES, INC.					+35.98%
	CELLTRION, INC.					+29.79%
	GENMAB A/S					+13.61%
	WUXI BIOLOGICS (CAYMAN) INC.					+26.56%
	Average					+20.86%
	Weighted average by Cap.					+21.93%

See all sector performances

Analysts' Consensus

Sell

Consensus

Buy

Mean consensus

UNDERPERFORM

Number of Analysts

1

Last Close Price

11.61USD

Average target price

13.00USD

Spread / Average Target

+11.97%

High Price Target

13.00USD

Spread / Highest target

+11.97%

Low Price Target

13.00USD

Spread / Lowest Target

+11.97%

Analyst Consensus Detail

Analyst consensus - Amarin Corporation plc

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Amarin Corporation plc

Stock Market
Stocks
AMRN Stock
Consensus Amarin Corporation plc

The best tools reserved for subscribers to boost the performance of your investments!

×